Milestone Pharmaceuticals Inc at Piper Sandler Healthcare Conference Transcript
My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. Thank you for joining us for our next presenting company, Milestone. Before we begin, I am required to point out certain disclosures regarding the relationship between Piper and Milestone that are located at the back of the room and also at the registration desk.
So Milestone is developing intranasal etripamil for the treatment of paroxysmal supraventricular tachycardia, or PSVT for short. Company recently reported positive Phase 3 RAPID data and is preparing to file an NDA for etripamil for PSVT in the middle of next year.
Here with us today is President and CEO, Joe Oliveto -- Joe, so good to see you -- and also Lorenz Muller, who's the Chief Commercial Officer. So guys, let's jump right into this. Perhaps you can start off by explaining PSVT. What is it? What do patients experience?
Thanks, Ted. And I want to thank the colleagues at Piper for inviting us
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |